Histopathological, Magnetic Resonance (MR) And Ultrasound Correlates Of Mammographic Density In BRCA1-2 Mutation Carriers
Funder
National Health and Medical Research Council
Funding Amount
$345,931.00
Summary
Mammographic density (MD), is a major risk factor for breast cancer. The nature of breast tissue underlying MD is not clear. The study will clarify the nature of breast tissue underlying MD as well as determining the breast MRI and ultrasound features that correlate with MD. These findings will enhance knowledge of breast cancer development, and should help to avoid mammography to screen young, high risk women and fulfil a priority objective of Cancer Australia
Automated Screening Measures Associated With Risk And Treatment (SMART) Of Breast Cancer
Funder
National Health and Medical Research Council
Funding Amount
$98,244.00
Summary
Women with greater mammographic density (white area on a mammogram) are at greater risk of breast cancer. Prof Hopper (supervisor) has led international research in this area using a method called CUMULUS. Drs Makalic and Schmidt (co-supervisors) have created an automated measure, called CIRRUS. My aims are to: find out which factors influence CIRRUS, confirm that CIRRUS predicts breast cancer risk, and develop automated measures of a breast cancer risk based on magnetic resonance imaging (MRI).
Automated Mammographic Measures That Predict Breast Cancer Risk
Funder
National Health and Medical Research Council
Funding Amount
$406,260.00
Summary
Mammographic density (MD) is one of the strongest predictors of breast cancer risk but its impractical measurement prevents its use in a clinical setting. An automated measure of MD would allow screening programs to identify and target women at higher risk of breast cancer which could lead to earlier diagnoses and better breast cancer outcomes. We aim to develop an automated measurement, maximized by its ability to predict breast cancer risk, and applicable to both film and digital mammograms.
Determination Of Diagnostic Molecular Profiles For Intraduct Lesions Of The Breast.
Funder
National Health and Medical Research Council
Funding Amount
$308,400.00
Summary
Breast cancer originates in cells within breast ducts. The introduction of Breast Screening for breast cancer has led to a dramatic increase in the diagnosis of breast cancer which is confined to these ducts and has not spread to surrounding tissue. This is known as 'ductal carcinoma in situ' or DCIS. It is evident that DCIS is variable in its tendency to give rise to more advanced breast cancer. However, currently our ability to predict the potential agressiveness of a particular DCIS is limite ....Breast cancer originates in cells within breast ducts. The introduction of Breast Screening for breast cancer has led to a dramatic increase in the diagnosis of breast cancer which is confined to these ducts and has not spread to surrounding tissue. This is known as 'ductal carcinoma in situ' or DCIS. It is evident that DCIS is variable in its tendency to give rise to more advanced breast cancer. However, currently our ability to predict the potential agressiveness of a particular DCIS is limited. In this research we are proposing to develop new methods for evaluation of DCIS that will more accurately predict clinical behaviour. An important adjunct is to ensure that these methods can be practically applied in a routine diagnostic setting. Achievement of the aims of this project will assist treatment planning for patients diagnosed with DCIS. It will also provide important information about breast cancers diagnosed as a consequence of breast screening.Read moreRead less
Apportioning Deficits In Bone Size And Density In Women With Fractures To Growth Or Ageing By Studies In Their Daughters
Funder
National Health and Medical Research Council
Funding Amount
$196,018.00
Summary
Women fracture their bones because the bones are small and break easily and because the bones are thin or low in denseness (very porous like a honey comb). This study is aimed at identifying why women with fractures have small bones and why the bones are so porous. They may have these problems because they lost a lot of bone as they get older or because growth was abnormal so the size of the bone didn't reach its potential size or because the denseness of the bones didn't develop properly. The s ....Women fracture their bones because the bones are small and break easily and because the bones are thin or low in denseness (very porous like a honey comb). This study is aimed at identifying why women with fractures have small bones and why the bones are so porous. They may have these problems because they lost a lot of bone as they get older or because growth was abnormal so the size of the bone didn't reach its potential size or because the denseness of the bones didn't develop properly. The study will be carried out in women with spine or hip fractures and their daughters. All participants will have bone densitometry, provide a 24 hour urine sample and a fasting blood sample of 20 ml whole blood. Informed consent will be obtained from all participants. The bone density scan is associated with radiation exposure of about 4 mSv, about one tenth of a chest x ray, temporary bruising may follow taking blood. If we can understand the different ways osteoporosis can occur we can then start to devise specific treatments tailored to the individual. Also if we can identify the causes of small bones and bone thinness during growth it may be possible to correct some of these causes before the reduced growth and reduced building of bone occurs. We might also prevent the thinning of bone by identifying and removing causes of bone thinning.Read moreRead less
Prediction Of Adverse Outcomes Following A Fragility Fracture
Funder
National Health and Medical Research Council
Funding Amount
$148,426.00
Summary
Individuals with an existing fracture are at increased risk of adverse outcomes such as re-fracture and premature mortality, but it is not clear why. We propose to evaluate risk factors, and prognostic models, for predicting the risk of adverse outcomes. We also propose to develop a quantitative risk-benefit framework for evaluating the clinical utility of such prognostic models and help ensure that therapies appropriately address real-life experience of osteoporotic patients.